ACADIA Pharmaceuticals Inc. [NASDAQ: ACAD] gained 3.32% or 1.49 points to close at $46.36 with a heavy trading volume of 2206431 shares. The company report on October 26, 2020 that Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and neurodegenerative diseases will be shared at the 13th Clinical Trials on Alzheimer’s Disease Conference (CTAD), being held virtually November 4-7, 2020.
Scientific presentations include those investigating pimavanserin treatment and its impact on cognition and motor function in patients with neuropsychiatric symptoms related to neurodegenerative diseases, including dementia-related psychosis. Other presentations include a comprehensive literature review of current use of antipsychotic treatment for dementia-related psychosis, an analysis of mortality risk and need for long-term care for patients with dementia-related psychosis versus patients with dementia only, and assessments of efficacy and safety of pimavanserin in dementia-related psychosis.
It opened the trading session at $45.00, the shares rose to $47.545 and dropped to $44.55, the range by which the price of stock traded the whole day. The daily chart for ACAD points out that the company has recorded -8.67% loss over the past six months. However, it is still -54.43% lower than its most recent low trading price.
If we look at the average trading volume of 1.17M shares, ACAD reached to a volume of 2206431 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about ACADIA Pharmaceuticals Inc. [ACAD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACAD shares is $59.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACAD stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for ACADIA Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on August 25, 2020. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Overweight. The new note on the price target was released on August 20, 2020, representing the official price target for ACADIA Pharmaceuticals Inc. stock. Previously, the target price had yet another raise from $41 to $71, while Stifel kept a Buy rating on ACAD stock.
The Average True Range (ATR) for ACADIA Pharmaceuticals Inc. is set at 1.53, with the Price to Sales ratio for ACAD stock in the period of the last 12 months amounting to 18.33. The Price to Book ratio for the last quarter was 10.93, with the Price to Cash per share for the same quarter was set at 4.24.
Trading performance analysis for ACAD stock
ACADIA Pharmaceuticals Inc. [ACAD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.50. With this latest performance, ACAD shares gained by 15.24% in over the last four-week period, additionally sinking by -8.67% over the last 6 months – not to mention a rise of 9.99% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACAD stock in for the last two-week period is set at 71.21, with the RSI for the last a single of trading hit 77.44, and the three-weeks RSI is set at 64.70 for ACADIA Pharmaceuticals Inc. [ACAD]. The present Moving Average for the last 50 days of trading for this stock 40.46, while it was recorded at 43.53 for the last single week of trading, and 44.05 for the last 200 days.
ACADIA Pharmaceuticals Inc. [ACAD]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and ACADIA Pharmaceuticals Inc. [ACAD] shares currently have an operating margin of -72.71 and a Gross Margin at +96.65. ACADIA Pharmaceuticals Inc.’s Net Margin is presently recorded at -69.38.
Return on Total Capital for ACAD is now -41.51, given the latest momentum, and Return on Invested Capital for the company is -39.72. Return on Equity for this stock declined to -39.93, with Return on Assets sitting at -35.55. When it comes to the capital structure of this company, ACADIA Pharmaceuticals Inc. [ACAD] has a Total Debt to Total Equity ratio set at 1.40. Additionally, ACAD Total Debt to Total Capital is recorded at 1.38, with Total Debt to Total Assets ending up at 1.25. Long-Term Debt to Equity for the company is recorded at 0.91, with the Long-Term Debt to Total Capital now at 0.90.
Reflecting on the efficiency of the workforce at the company, ACADIA Pharmaceuticals Inc. [ACAD] managed to generate an average of -$467,712 per employee. Receivables Turnover for the company is 10.33 with a Total Asset Turnover recorded at a value of 0.51.ACADIA Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.40 and a Current Ratio set at 8.50.
ACADIA Pharmaceuticals Inc. [ACAD]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, ACADIA Pharmaceuticals Inc. posted -0.29/share EPS, while the average EPS was predicted by analysts to be reported at -0.4/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 27.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACAD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ACADIA Pharmaceuticals Inc. go to 25.00%.
An analysis of insider ownership at ACADIA Pharmaceuticals Inc. [ACAD]
There are presently around $7,076 million, or 98.80% of ACAD stock, in the hands of institutional investors. The top three institutional holders of ACAD stocks are: BAKER BROS. ADVISORS LP with ownership of 41,904,586, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; FMR LLC, holding 20,790,304 shares of the stock with an approximate value of $963.84 million in ACAD stocks shares; and PRICE T ROWE ASSOCIATES INC /MD/, currently with $525.8 million in ACAD stock with ownership of nearly -4.11% of the company’s market capitalization.
Positions in ACADIA Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 168 institutional holders increased their position in ACADIA Pharmaceuticals Inc. [NASDAQ:ACAD] by around 13,285,744 shares. Additionally, 127 investors decreased positions by around 15,902,252 shares, while 38 investors held positions by with 123,451,722 shares. The mentioned changes placed institutional holdings at 152,639,718 shares, according to the latest SEC report filing. ACAD stock had 81 new institutional investments in for a total of 3,449,409 shares, while 32 institutional investors sold positions of 2,166,201 shares during the same period.